» Articles » PMID: 39261343

Germline P.R181H Variant in TP53 in a Family Exemplifying the Genotype-phenotype Correlations in Li-Fraumeni Syndrome

Overview
Journal Fam Cancer
Publisher Springer
Specialty Oncology
Date 2024 Sep 11
PMID 39261343
Authors
Affiliations
Soon will be listed here.
Abstract

Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with germline pathogenic/likely pathogenic variants in TP53. Genotype-phenotype correlations are progressively being characterized in LFS with certain TP53 variants associated with attenuated penetrance and phenotypes. We report on a family harboring a TP53 p.R181H variant presenting with a restricted cancer phenotype in adulthood. The proband was a female with breast cancer at the age of 71 years who had three first degree relatives also diagnosed with breast cancer after the age of 40 years (mother, two sisters). Of the nine individuals harboring the variant (6 genetically confirmed, 3 obligate heterozygous), six have not developed malignancies at this time (age range: 36-42). No childhood-onset cancers were reported in this family. A concomitant literature review identified 51 additional individuals harboring the p.R181H variant in TP53, presenting a tumor phenotype dominated by breast cancer. Rare occurrences of other adult-onset cancers (prostate, colorectal and thyroid) and only few childhood onset cancer were documented. These observations are consistent with functional analysis showing that p.R181H retains partial p53 function and suggesting possible reduced cancer penetrance, particularly in the pediatric setting.

References
1.
Bougeard G, Renaux-Petel M, Flaman J, Charbonnier C, Fermey P, Belotti M . Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol. 2015; 33(21):2345-52. DOI: 10.1200/JCO.2014.59.5728. View

2.
Amadou A, Achatz M, Hainaut P . Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol. 2017; 30(1):23-29. DOI: 10.1097/CCO.0000000000000423. View

3.
Pinto E, Zambetti G . What 20 years of research has taught us about the TP53 p.R337H mutation. Cancer. 2020; 126(21):4678-4686. PMC: 7589304. DOI: 10.1002/cncr.33143. View

4.
Kratz C, Freycon C, Maxwell K, Nichols K, Schiffman J, Evans D . Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis. JAMA Oncol. 2021; 7(12):1800-1805. PMC: 8554692. DOI: 10.1001/jamaoncol.2021.4398. View

5.
Fortuno C, Pesaran T, Mester J, Dolinsky J, Yussuf A, McGoldrick K . Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing. Cancer Genet. 2020; 248-249:11-17. DOI: 10.1016/j.cancergen.2020.09.002. View